Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|February 4, 2003
Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applicationsAndreas Hüser, Christian Hofmann
Current Gene Therapy|July 12, 2002
Advances in the development of non-human viral DNA-vectors for gene deliveryPeter Löser, Andreas Hüser, Moritz Hillgenberg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 14, 2006
Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite proteinRobert Strauss, Andreas Hüser, Shaoheng Ni, et al.
European Journal of Clinical Pharmacology|November 12, 2017
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseasesFredrik N Albach, Frank Wagner, Andreas Hüser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)Carey Hwang, Dirk Schürmann, Christian Sobotha, et al.
The Lancet. HIV|January 9, 2020
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialDirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, et al.
Annals of the Rheumatic Diseases|March 4, 2019
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicityThomas Dörner, Maximilian Georg Posch, Yue Li, et al.
AIDS Research and Human Retroviruses|September 18, 2024
A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected ParticipantsDirk Schürmann, Andreas Hüser, Frieder Pfäfflin, et al.
Clinical Therapeutics|April 29, 2018
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3Wendy W Yeh, Iain P Fraser, Patricia Jumes, et al.
Pageof 1